Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of “Hold” by Analysts

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) has been given an average rating of “Hold” by the five research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $38.3333.

PHAR has been the subject of several recent research reports. Wall Street Zen lowered Pharming Group from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Oppenheimer reiterated an “outperform” rating and issued a $41.00 price target (down from $42.00) on shares of Pharming Group in a research report on Friday, March 13th. Weiss Ratings lowered Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Zacks Research upgraded Pharming Group from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Finally, Canaccord Genuity Group initiated coverage on Pharming Group in a research report on Friday, April 10th. They set a “buy” rating and a $37.00 target price for the company.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC purchased a new position in shares of Pharming Group during the second quarter valued at approximately $32,000. SmartHarvest Portfolios LLC purchased a new position in shares of Pharming Group during the fourth quarter valued at approximately $224,000. Millennium Management LLC purchased a new position in shares of Pharming Group during the fourth quarter valued at approximately $360,000. Finally, NewEdge Advisors LLC boosted its position in shares of Pharming Group by 11,310.3% during the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after buying an additional 28,615 shares during the period. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Trading Down 4.9%

PHAR opened at $12.99 on Friday. The firm has a market cap of $917.35 million, a P/E ratio of 81.19 and a beta of 0.04. Pharming Group has a 12 month low of $9.54 and a 12 month high of $21.34. The company has a current ratio of 2.63, a quick ratio of 2.06 and a debt-to-equity ratio of 0.35. The stock has a 50-day moving average of $15.38 and a 200 day moving average of $16.47.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.12). The company had revenue of $72.45 million during the quarter, compared to analysts’ expectations of $92.06 million. Pharming Group had a return on equity of 4.64% and a net margin of 3.30%. As a group, research analysts forecast that Pharming Group will post 0.6 EPS for the current year.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.